PUBLISHER: The Business Research Company | PRODUCT CODE: 1662357
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662357
A swine vaccine is a formulation given or injected into pigs to provoke an immune response against a particular infectious agent. These vaccines play a vital role in preventing diseases that can adversely affect pig health, productivity, and overall herd management.
The primary types of swine vaccines include attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. Attenuated live vaccines consist of weakened living viruses or bacteria that have been altered to reduce their pathogenicity. These vaccines aim to trigger a robust immune response in pigs by replicating within the body, leading to prolonged immunity. They are effective against various diseases including viral, bacterial, parasitic, and fungal infections. Swine vaccines are distributed through veterinary hospitals, veterinary pharmacies, and online pharmacies. These products are available through government tenders and sales in the market.
The swine vaccines market research report is one of a series of new reports from The Business Research Company that provides swine vaccines market statistics, including swine vaccines industry global market size, regional shares, competitors with a swine vaccines market share, detailed swine vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the swine vaccines industry. This swine vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The swine vaccines market size has grown strongly in recent years. It will grow from $2.18 billion in 2024 to $2.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to disease outbreaks, economic losses, government regulations, increased swine production.
The swine vaccines market size is expected to see strong growth in the next few years. It will grow to $3.44 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging diseases and viral strains, globalization of swine industry, climate and environmental changes, biosecurity measures, market competition. Major trends in the forecast period include veterinary advancements, evolving disease patterns, global demand for protein, technological advancements, preventive healthcare focus.
The growing incidence of diseases in swine is anticipated to drive the swine vaccine market in the future. Swine disease refers to any deviation from the normal structural or functional condition of an organism, often accompanied by signs and symptoms of ailments such as pseudorabies and influenza. Swine vaccines effectively address the increasing prevalence of these diseases by stimulating the immune system to recognize and respond to specific pathogens, thus reducing infection rates, alleviating disease severity, and promoting overall herd health. For example, in December 2023, the Swine Health Information Center, a US-based organization, reported a concerning rise in cases of African Swine Fever (ASF) among wild boars in Poland. By early 2023, the country had recorded 2,347 confirmed ASF cases in wild boars, surpassing the total from 2022. Consequently, the rising prevalence of diseases in swine is expected to boost market growth.
The rising global consumption of pork is expected to contribute to the growth of the swine vaccine market in the future. Pork consumption involves individuals incorporating pork into their diet through the preparation and consumption of various pork products sourced from pigs. Swine vaccines are essential for maintaining the health of pig populations, minimizing the risk of disease outbreaks, and ensuring the production of safe, high-quality pork worldwide. For instance, in March 2023, the Food and Agriculture Organization, an Italy-based federal organization, stated that pork constituted approximately 36% of the meat consumed globally, totaling 112.6 kilotons, with projections to increase to 129 kilotons by 2031. Therefore, the rising global pork consumption is driving the growth of the swine vaccine market.
Technological innovation is a significant trend gaining traction in the swine vaccine market. Leading companies are focusing on developing advanced technologies that enable the simultaneous delivery of two vaccines to enhance swine health and maintain their market position. For instance, in May 2022, Boehringer Ingelheim, a Germany-based pharmaceutical firm, introduced TwistPak technology. TwistPak is a groundbreaking platform that combines two vaccines, IngelvacCircoFLEX and IngelvacMycoFLEX, specifically for swine producers. This technology provides a convenient and time-efficient solution, facilitating a simplified mixing process while allowing flexibility to use the products either as a combined vaccine or as individual monovalent options. It is produced using advanced technologies and features an ergonomic design.
Prominent companies in the swine vaccine market are increasingly prioritizing the introduction of innovative vaccines, such as Circumvent CML, to enhance their competitive advantage. Circumvent CML is a vaccine aimed at safeguarding swine herds against various diseases, thereby improving overall swine health and productivity. For example, in June 2023, Merck Animal Health, a US-based pharmaceutical company, launched a new 3-in-one swine vaccine named Circumvent CML, which addresses the diseases caused by Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. This new vaccine is founded on Merck's established, proven antigens and adjuvant systems that have been utilized in Circumvent PCV-M G2 and their standalone product, Porcilis Ileitis.
In July 2024, MSD Animal Health, a US-based biopharmaceutical firm, acquired Elanco's aqua business for $1.3 billion. Through this acquisition, MSD Animal Health aims to substantially strengthen its presence in the aquaculture sector by broadening its range of products and solutions designed to enhance fish health, welfare, and sustainability. Elanco is a US-based pharmaceutical company that specializes in providing vaccine solutions for swine.
Major companies operating in the swine vaccines market are Merck & Co Inc., Boehringer Ingelheim Animal Health USA Inc., Elanco Animal Health Inc., Biogenesis Bago SA, Phibro Animal Health Corporation, KM Biologics Co. Ltd., Hipra Laboratories SA, Ceva Sante Animale SA, Zoetis Inc., Jinyu Bio-Technology Co. Ltd., China Animal Husbandry Industry Co. Ltd., Virbac SA, Harbin Veterinary Research Institute, Bioveta AS, Bimeda Holdings PLC, Biovac Ltd., Hester Biosciences Limited, Hygieia Biological Laboratories, IDT Biologika GmbH, Intervet Inc., Komipharm International Co. Ltd., Kyoritsu Seiyaku Corporation, Lohmann Animal Health International, Norbrook Laboratories Limited, Ouro Fino Saude Animal SA, Prondil SA, Vaxxinova International BV, Vetoquinol SA, Veyx Pharma GmbH, Tianjin Ringpu Bio-Technology Co. Ltd.
North America was the largest region in the swine vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the swine vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the swine vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The swine vaccine market consists of sales of haemophilus parasuis, pasteurella, salmonella, and streptococcus suis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Swine Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on swine vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for swine vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The swine vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.